Showing 1–12 of 24 results
Quetiapine for the Management of Tardive Dyskinesia in Schizoaffective Disorder Comorbid With Diabetes Mellitus and Chronic Kidney Disease
In this report, the authors describe the successful management of tardive dyskinesia with quetiapine in a man with schizoaffective disorder and comorbid diabetes with renal and neurologic complications as well as hypothyroidism and hypertension.
Measurement-based care (MBC) has been found to be effective in patients with psychiatric conditions. In this CME activity, learn how Dr Joseph McEvoy employs MBC for patients with tardive dyskinesia.
Collaborating With Patients to Make Treatment Decisions Based on Benefits and Risks of Medications Associated With Tardive Dyskinesia
Do you know how to talk with your patients about the risk for tardive dyskinesia? Follow along as Dr Nierenberg offers tips for clear communication.
Read an article on how to reduce Tardive dyskinesia (TD) symptoms, including the use of the FDA-approved treatment options (valbenazine and deutetrabenazine).
What should you rule out to diagnose tardive dyskinesia (TD)? How do treatment options differ? In this journal CME activity, Drs Citrome and Saklad team up to review the best clinical strategies.
Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Follow along as expert Joseph P. McEvoy, MD, reviews the evidence.
Your patient runs out of his antidepressant and a week later his mouth hurts. At presentation, you realize it's because his mouth is constantly twitching and he's been biting his cheeks. He was not taking an antipsychotic, so what's causing it, but more importantly, how do you stop it?
Tardive dyskinesia, a side effect of antipsychotics, is a persistent and disabling problem among patients with schizophrenia. Could a switch to clozapine help? This meta-analysis looks at 16 studies to evaluate the current evidence.
Although levodopa is effective for treating Parkinson disease, physicians and patients face significant management challenges related to disease progression. Patients may develop fluctuations in motor symptoms and dyskinesias as well as nonmotor symptoms. Review this CME Brief Report activity to learn about new and emerging treatment options to manage patients' symptoms.
Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop
The authors of this consensus statement look at the history of the use of the Abnormal Involuntary Movement Scale in tardive dyskinesia studies and outline the challenges of using AIMS results in clinical practice. They then propose different methods for reporting AIMS data that may provide broader and more clinically relevant perspectives.
Vitamin E is one of many antioxidants used for the treatment of tardive dyskinesia. It has been suggested that long-term vitamin E therapy may increase risk for prostate cancer, which is concerning given that high doses are used to treat tardive dyskinesia. Read this case report to find out more about this important topic.